Technology Listings


TrkB Agonists for the Treatment of Obesity and Neurological Diseases

Application

Catecholamine derivatives, methods and compositions effective for the treatment of obesity and neurological diseases and disorders.

Key Benefits
  • Catecholamine derivatives for the treatment of metabolic disorders, such as obesity, have been developed.
  • Catecholamine derivatives promote neuroprotection and may be useful in the prevention and/or treatment of ALS, Parkinson's disease, Alzheimer's disease and other neurological diseases and disorders.
Technical Summary

Neurotrophins are a family of proteins that induce the survival, development and function of neurons. One such neurotrophin, brain-derived neurotrophic factor (BDNF), is a natural tyrosine kinase B (TrkB) ligand. BDNF binds to TrkB increasing neuronal cell survival, differentiation and synaptic plasticity.

Dr. Keqiang Ye has identified catecholamine derivatives that act like BDNF and activate the TrkB receptor.  The compounds and methods could be useful for neuroprotective therapy, treatment of various neurological diseases, and treatment or prevention of obesity. For example, Dr. Ye has demonstrated that, in mouse models of obesity, activation of TrkB receptors reduces appetite and body weight in a dose-dependent manner.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Continuation United States 14/336,911 9,266,817 3/17/2014 2/23/2016  
Tech ID: 09025
Published: 10/11/2010
Category
Therapeutics

Contact
Cliff Michaels
Assistant Director
Emory University
404-727-3890
ccmicha@emory.edu

Inventor(s)
Keqiang Ye

Keywords
Metabolic Diseases
Neuroscience/Pain
Small Molecule